Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants

Saved in:
Bibliographic Details
Published inThe World Allergy Organization journal Vol. 13; no. 8; p. 100267
Main Authors Ellis, Anne K., Murrieta-Aguttes, Margarita, Furey, Sandy, Carlsten, Christopher
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.08.2020
Elsevier
Online AccessGet full text
ISSN1939-4551
1939-4551
DOI10.1016/j.waojou.2020.100267

Cover

More Information
ISSN:1939-4551
1939-4551
DOI:10.1016/j.waojou.2020.100267